# Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain

> **NCT04666714** · PHASE3 · RECRUITING · sponsor: **EMS** · enrollment: 136 (estimated)

## Conditions studied

- Neuropathic Pain

## Interventions

- **DRUG:** Praga formulation
- **OTHER:** Placebo pregabalin 75mg
- **OTHER:** Placebo Pregabalin 150mg
- **DRUG:** Pregabalin 75mg
- **DRUG:** Pregabalin 150mg
- **OTHER:** Placebo Praga formulation

## Key facts

- **NCT ID:** NCT04666714
- **Lead sponsor:** EMS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-15
- **Primary completion:** 2025-09-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04666714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04666714, "Efficacy and Safety of Praga Formulation in the Treatment of Neuropathic Pain". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04666714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*